Regina Brown - Jun 30, 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Director
Signature: /s/ Regina Brown
Stock symbol: LIXT
Transactions as of: Jun 30, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/7/2023, 10:57 AM
Previous filing: Nov 22, 2022
Next filing: Jul 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+10K	$0.00	10K	Jun 30, 2023	Common	10K	$5.88	Direct	F1
holding	LIXT	Options to Purchase Common Stock					10K	Jun 30, 2023	Common	10K	$7.45	Direct
holding	LIXT	Options to Purchase Common Stock					10K	Jun 30, 2023	Common	10K	$30.30	Direct
holding	LIXT	Options to Purchase Common Stock					25K	Jun 30, 2023	Common	25K	$28.00	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.

Content

Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.